Theravance Biopharma (TBPH) Earnings Analysis

Theravance Biopharma (TBPH) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it missed with EPS -0.0962 USD vs 0.028 USD est (-443.6%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E 7.43.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TBPH next report earnings?

No confirmed upcoming earnings date is currently scheduled for TBPH. This page updates as the calendar is published.

TBPH earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.0962 USD0.028 USD-443.6%Miss
2026-03-190.06 USD0.44 USD-86.4%Miss
2025-11-100.04 USD-0.03 USD+233.3%Beat
2025-05-08-0.17 USD-0.11 USD-54.5%Miss
2025-02-26-0.05 USD-0.05 USD0%Beat
2024-08-05-0.13 USD-0.09 USD-44.4%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

TBPH valuation and analyst view

Trailing P/E7.43
Trailing EPS2.234 USD
Price / book2.97
Dividend yield0.00%
Market cap0.87B
Analyst consensusHold (4 buy / 10 hold / 3 sell)
Avg price target17 USD

Related research pages

Frequently asked questions

When is Theravance Biopharma (TBPH)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for TBPH. This page updates as the calendar is published.

Did TBPH beat earnings last quarter?

In its 2026-05-07 report, TBPH posted EPS of -0.0962 USD versus a 0.028 USD estimate — a miss of 443.6%.

What is TBPH's earnings track record?

Over the last 6 reported quarters with consensus data, TBPH beat estimates 2 times (33%).

What is TBPH's current P/E ratio and EPS?

TBPH trades at a trailing P/E of 7.43 on trailing EPS of 2.2336824041030443 USD.

What do analysts rate TBPH?

Analyst consensus is "Hold" across 17 ratings (0 strong buy, 4 buy, 10 hold, 3 sell, 0 strong sell). Average 12-month price target: 17 USD.